

April 28, 2026

<b>DCS-CRD</b> <b>BSE Limited</b> First Floor, New Trade Wing Rotunda Building, Phiroze Jeejeebhoy Towers Dalal Street, Fort Mumbai 400001 Fax No.2272 3121/2037/2039  Stock Code: 543213	<b>Listing Compliance</b> <b>National Stock Exchange of India Limited</b> Exchange Plaza, 5 <sup>th</sup> Floor Plot No. C/1, 'G' Block, Bandra- Kurla Complex Bandra East Mumbai 400051 Fax No.2659 8237/8238  Stock Code: ROSSARI
--	--

Dear Sir/Madam,

**Subject: Q4 & FY26 Press Release**

Please find enclosed a copy of the Press Release for the Quarter and Financial Year ended March 31, 2026.

The same may please be taken on record and suitably disseminated to all concerned.

Thanking you,

Yours Sincerely,

**For Rossari Biotech Limited**



Parul Gupta  
**Company Secretary & Head - Legal**  
Membership No.: A38895

Encl.: as above

**ROSSARI BIOTECH LIMITED**

(An ISO 9001:2015 & 14001:2015 Certified Company) (CIN: L24100MH2009PLC194818)

**Regd. Office:** Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai - 400079, Maharashtra, India. T: +91-22-6123 3800

**Factory :** Plot No. 10 & 11, Survey No. 90/1/10 & 90/1/11/1, Khumbharwadi, Village Naroli, Silvassa - 396235, Dadra & Nagar Haveli (U.T.), India. T: 0260-669 3000

: Plot No. D3-24-2 & D3-24-3, Phase III, GIDC Dahej, Village Galenda, Taluka Vagra, Bharuch, Gujarat - 392130, India. T: +91-2641-661621

✉ info@rossari.com

🌐 www.rossari.com



## Rossari Biotech Limited

**Corporate Office:** Rossari House, Golden Oak, LBS Marg, Surya Nagar, Opp. Mahindra Showroom, Vikhroli (West), Mumbai – 400079, Maharashtra, India

### Rossari Biotech announces Q4 FY26 results

#### Q4 FY26

#### Highest Quarterly Performance

**Revenues at Rs. 684.9 Cr, up 18% YoY**

**EBITDA at Rs. 77.3 Cr, up 11% YoY**

**PAT at Rs. 46.0 Cr, up 34% YoY**

**Mumbai, April 27, 2026:** Rossari Biotech Limited (Rossari), a Specialty-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries, has announced its financial results for the quarter ended March 31, 2026.

#### Consolidated: Q4 FY26 performance overview compared with Q4 FY25

- Revenue from operations grew 18% to Rs. 684.9 crore as compared to Rs. 579.6 crore
- EBITDA improved by 11% to Rs. 77.3 crore from Rs. 69.5 crore
  - o EBITDA margin at 11.3% as against 12.0%
- PAT increased by 34% to Rs. 46.0 crore from Rs. 34.4 crore
- EPS (Diluted) stood at Rs. 8.29\* as against Rs. 6.21\*

#### Consolidated: FY26 performance overview compared with FY25

- Revenue from operations stood at Rs. 2,396.4 crore as against Rs. 2,080.3 crore, up 15%
- EBITDA increased by 8% to Rs. 286.0 crore as against Rs. 265.1 crore
  - o EBITDA margin at 11.9% as against 12.7%
- PAT higher by 9% to Rs. 149.2 crore as against Rs. 136.4 crore
- EPS (Diluted) stood at Rs. 26.93 as against Rs. 24.63

**Note:**

- 1) All figures, unless mentioned otherwise, are on a consolidated basis
- 2) \* EPS not annualized

**Commenting on the performance, in a joint statement, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, said**

*“We concluded the year on a strong note, with Q4 FY26 marking our highest-ever quarterly revenue and EBITDA performance. All our business segments, HPPC, TSC and AHN, delivered healthy double-digit growth during the quarter, reflecting the strength of our diversified portfolio and our ability to execute well across end-user industries.*

*Our diversified portfolio and balanced presence across end-user industries helped us navigate a mixed operating environment, including volatility arising from the ongoing geopolitical conflict, while sustaining growth. Margins during the quarter were impacted by the prevailing raw material situation and the lag in passing on cost inflation. We remain focused on calibrated pricing actions, improving product mix and driving operating leverage, which should support margin recovery over time.*

*We continue to strengthen our manufacturing base in a calibrated manner. During the quarter, Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at Dahej, taking total installed ethoxylation capacity to 66,000 MTPA. Our earlier capex plans announced in April 2025, have been rephased over the next two years to align with evolving business requirements and market conditions, while maintaining the overall strategic intent.*

*As we look ahead, our focus remains on disciplined execution, customer-led innovation and profitable growth. With strong R&D capabilities, expanding capacities, a healthy balance sheet and sharper strategic alignment across businesses, we are well placed to build an integrated, intelligent and impactful specialty chemicals platform and deliver sustained value for all our stakeholders.”*

### **Key Developments**

---

- Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at its Dahej facility on 31 March 2026, taking total installed ethoxylation capacity to 66,000 MTPA
- For FY 2025-26, the Board of Directors recommended a dividend of Re. 0.50 per share
- Appointment of Mr. Udeypaul Singh Gill, as an Additional Director designated as Non-Executive, Independent Director of the Company
- The Company has set up a new Research and Development Facility located at Koparkhairane, Navi Mumbai and also shifted its existing Research and Development Facility located at IIT Bombay. This transition marks a significant step-up in scale and ambition, positioning the Company to drive faster innovation cycles and strengthen its competitive moat.

**Note:** Home, Personal Care and Performance Chemicals (HPPC); Textile Specialty Chemicals (TSC); Animal Health and Nutrition (AHN)

**< Ends >**

## About Rossari Biotech Limited:

---

Rossari Biotech Limited (Rossari) (BSE: 543213, NSE: ROSSARI), is a Speciality-Chemicals manufacturer providing intelligent and sustainable solutions for customers across industries. Headquartered at Mumbai, India, the Company operates strategically located manufacturing facilities at Silvassa and Dahej. The Company offers tailor-made solutions for Home, Personal Care and Performance chemicals (HPPC), Textile speciality chemicals and Animal Health and Nutrition (AHN). With differentiated product offerings, Rossari caters to an array of applications across FMCG, Home care, Industrial Cleaning, Personal Care, Textile Speciality Chemicals, Performance Chemicals, the Animal Health and Nutrition and Pet Care businesses. The Company has an extensive and a dedicated network of distributors spread all over India.

---

For more information, please visit [www.rossari.com](http://www.rossari.com) OR contact:

---

**Ketan Sablok**

Rossari Biotech Limited

Tel: +91 22 6123 3800

Email: [ketan.sablok@rossari.com](mailto:ketan.sablok@rossari.com)

**Anoop Poojari / Mitesh Jain**

CDR India

Tel: +91 98330 90434 / 96194 44691

Email: [anoop@cdr-india.com](mailto:anoop@cdr-india.com) /  
[mitesh@cdr-india.com](mailto:mitesh@cdr-india.com)

---

## DISCLAIMER:

---

*Certain statements and opinions with respect to the anticipated future performance of Rossari Biotech Limited in the press release ("forward-looking statements"), which reflect various assumptions concerning the strategies, objectives and anticipated results may or may not prove to be correct. Such forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changes in economic, political, regulatory, business or other market conditions. Such forward-looking statements only speak as at the date the press release is provided to the recipient and Rossari Biotech Limited is not under any obligation to update or revise such forward-looking statements to reflect new events or circumstances. No representation or warranty (whether express or implied) is given in respect of any information in this press release or that this press release is suitable for the recipient's purposes. The delivery of this press release does not imply that the information herein is correct as at any time subsequent to the date hereof and Rossari Biotech Limited has no obligation whatsoever to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent subsequent to the date hereof.*